Roche Holding AG (ROG.SW) stock: key figures, P/E, revenue and dividend
Switzerland · ISIN CH1499059983
Roche Holding AG financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 62.40 bn CHF | 61.52 bn CHF |
| Gross profit | 46.11 bn CHF | 45.24 bn CHF |
| EBIT | 13.42 bn CHF | 19.26 bn CHF |
| Net income | 8.28 bn CHF | 12.88 bn CHF |
| Diluted EPS – continuing operations | 10.32 CHF | 16.04 CHF |
Full history since 1995, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagnostic instruments; and digital health solutions. Roche Holding AG has a collaboration agreement with Excalipoint Therapeutics to evaluate EXP011 in DLL3-expressing solid tumors. The company was founded in 1896 and is based in Basel, Switzerland.
More stocks
- UnitedHealth Group (UNH)
- Bank of America (BAC)
- Dell Technologies (DELL)
- Caterpillar Inc. (CAT)
- Repay Holdings Corp (RPAY)
- PetroChina Co Ltd Class A (601857.SS)
- HSBC Holdings PLC ADR (HSBC)
- HSBC Holdings PLC (HSBA.L)
- China Mobile Limited (600941.SS)
- Philip Morris International (PM)
- GE Aerospace (GE)
- Shell PLC (SHEL.L)
Not investment advice. All data without warranty, price as of 12.09.2026. Details in the risk notice.